Release date: 2017-05-11
DBS System is a Swiss-based startup that produces the HemaXis portable blood test system. The latest news The company received $2.5 million in investment, of which Investiere invested $800,000, the Swiss pension fund Nest invested $700,000, and another $1 million from existing shareholders and angel investors.
DBS uses microfluidic technology to obtain more information from dried blood than traditional blood tests, making home testing easier. Its test method called "microsample" also requires less blood volume than existing methods.
The company's first generation of HemaXi equipment, HemaXis DB, is already available in Europe, and the company is building partnerships with companies in Europe and the United States. The financing was mainly for the development of a second-generation device called HemaXis DP, which passively separates plasma from serum without centrifugation or filtration.
“Our technical advantage is obvious: anyone can use it in a non-medical environment, reliable, safe and standardized blood samples, streamline logistics, and comply with existing workflows, all of which reduce laboratory costs.†Company CEO Eric Ddman said in a statement. “This model is beneficial to us and our partners because they can expand their markets by reaching more patients and sell our equipment through their distribution network, which is estimated to reach $20 billion.
There are also many companies that are trying to revolutionize blood testing methods. At this year's CES conference, Seventh Sense Biosystems introduced their TAP device, which takes blood in two to three minutes without the need for a large needle. In addition, there are some home experiment test providers, such as Everlywell and myLabBox, which indicate that they are trying to get more insights from blood tests.
Of course, the field of blood testing is mixed. Founded in 2003, Theranos has created an empire for blood testing with its finger puncture detection technology, and its valuation has soared to $9 billion. However, Pulitzer Prize winner John Carreyrou's article in the Wall Street Journal pierced the illusory bubble. The article quoted the company's former employees as saying that only a small part of the blood was tested by Theranos' own Edison machine test, and the other 190 items were traditionally used. test. Subsequently, the investigation of the Theranos laboratory in Newark will be revoked by the US Federal Health Insurance and Federal Medical Service Center (CMS). After Theranos, many investors have a lingering fear in this field, and it is not easy to convince investors to enter this field.
Source: 36æ°ª
Alginate Dressing,Silver Alginate,Alginate Wound Dressing,Alginate Dressing For Wound Care
Henan Maidingkang Medical Technology Co.,Ltd , https://www.mdkmedicales.com